38 results about "HEART INFARCTION" patented technology

The present invention provides compositions and methods based on genetic polymorphisms that are associated with cardiovascular diseases, particularly coronary heart disease (especially myocardial infarction) or hypertension. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.

The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.

Ortho methoxy phenolic compounds are provided that include methylenedioxyphenyl ferulate and ferulylproline and derivatives thereof. Pharmaceutical compositions comprising the compounds and methods of using the compounds for treating cardiovascular diseases, including hypertension, atherosclerosis, coronary heart disease, angina, stroke, and myocardial infarction, are further provided. The compounds are also useful in reducing low-density lipoprotein oxidation, improving or increasing vasodilation, and reducing plaque destabilization in a subject.

The invention discloses a detection method in the technical field of biological engineering, in particular a method for diagnosing cardiac troponin I (cTn I) in a semi-quantitative mode by employing double-indicatrix immunochromatography. Acute myocardial infarction (AMI) is a serious disease in a coronary heart disease, is a common emergency among middle-aged and elderly people, and is high in death rate. According to statistics, one third to a half of patients die before being sent to a hospital. In the next 20 years, the AMI is a primary cause for death of the patients around the world. The cTn I is a reliable index which is currently acknowledged and has the highest specificity and the longest duration for myocardial infarction diagnosis. At present, cTn I detection methods which are commonly used in clinic comprise an enzyme-linked immunosorbent assay method and a radioimmunoassay method, which are time-saving, labor-saving, difficult to popularize and high in cost. An immune colloidal gold technology is quickly developed in recent years and can be widely applied to detection of communicable diseases, early pregnancy and cancers. By employing colloidal gold immunochromatography, a quick detection method for the cTn I is established. By adoption of the method, a cTn I gray area of 1 to 5 ng / ml can be subjected to semi-quantitative detection.

The invention discloses a pure plant traditional Chinese medicinal preparation for treating myocardial infarction and cardiovascular diseases and a preparation method thereof. The preparation comprises the following traditional Chinese medicinal components by weight: 6-15g of codonopsis pilosula, 6-15g of astragalus membranaceus, 6-15 parts of ligusticum wallichii, 8-15g of liquorice, 8-15g of pseudo-ginseng and 50-150ml of gingko leaf extract. The preparation method comprises the following steps: quenching the traditional Chinese medicinal materials for about 4 hours according to the requirement on dosage and quantity; uniformly stirring, adding the gingko leaf extract, and mixing; pouring the mixture in a traditional Chinese medicament extraction bag, putting the bag in a high-pressure kettle, and gradually heating to 105-115 DEG C; cooling to 100 DEG C in the high-pressure kettle, sealing and filling the liquid medicine into a finished product with 50-100ml in each bag to obtain the solution preparation; and storing at normal temperature. The pure plant traditional Chinese medicinal preparation can be used for improving micro-circulation of a human body, eliminating oxygen radicals, remarkably increasing the heart coronary blood flow, remarkably promoting brain blood circulation, increasing brain blood flow rate and regulating blood fat, so that the blood viscosity can be reduced, blood circulation can be improved, and the aging process of a human body can be delayed. The pure plant traditional Chinese medicinal preparation adopts pure plant traditional Chinese medicinal materials, is restrict in formula, mild in action, low in cost and small in dosage, gradually plays drug effects, and does hurt the liver or kidney of a patient.

VEGF-B is shown to be needed for cardiac muscle revascularization after heart infarction, and methods of promoting or stimulating vascular development, e.g. angiogenesis and / or arteriogenesis, particularly in ischemic mammals, are disclosed.

The present invention relates to a compound of the following formula (I): as well as its process of preparation, pharmaceutical and cosmetics composition comprising it and use thereof, notably as an inhibitor of the sodium-dependent glucose co-transporter, such as SGLT1, SGLT2 and SGLT3, in particular in the treatment or prevention of diabetes, and more particularly type-II diabetes, diabetes-related complications, such as arthritis of the lower extremities, cardiac infarction, renal insufficiency, neuropathy or blindness, hyperglycemia, hyperinsulinemia, obesity, hypertriglyceridemia, X syndrome and arteriosclerosis, as well as for its use as an anticancer, anti-infective, anti-viral, anti-thrombotic or anti-inflammatory drug, or for lightening, bleaching, depigmenting the skin, removing blemishes from the skin, particularly age spots and freckles, or preventing pigmentation of the skin.

The present invention relates to the use of elafin for the treatment and / or prevention of diseases or disorders associated with an increase in troponin levels, which are non elastase dependent. The present invention in a preferred embodiment relates to a method and composition, using elafin, for protecting the heart muscle or other muscles from damage induced by abnormal blood flow and / or inflammation, which may result from, for example, a heart infarction. The present invention additionally or concomitantly relates to the use of elafin for the treatment and / or prevention of disorders or diseases which are associated with a rise in the level of troponin I and / or T.

The present invention relates to methods of identifying whether a candidate compound is a modulator of an orphan G protein-coupled receptor (GPCR). Preferably the GPCR is human. In some embodiments, the GPCR is expressed endogenously by cardiomyocytes. In some embodiments, the GPCR is coupled to Gi and lowers the level of intracellular cAMP. In some embodiments, overexpression of the GPCR promotes survival of cardiomyocytes. In some embodiments, overexpression of the GPCR rescues cardiomyoctes from hypoxia / reoxygenation induced apoptosis. In some embodiments, the GPCR is down-regulated in individuals with congestive heart failure. Agonists of the invention are envisioned to be useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure.

The present invention relates to the use of an hydrogel comprising silylated biomolecule for the three-dimensional culture of cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and to an aqueous composition comprising i) cardiomyocytes or stem cells which are able to differentiate into cardiomyocytes, and ii) a hydrogel comprising silylated biomolecule, for use for treating heart failure, in particular heart failure following myocardial infarction.

A therapeutic and / or preventing agent for a disease due to vascular constriction or vasodilation comprising a EDG-5 modulator. Since EDG-5 modulator specifically binds EDG-5 and shows antagonistic or agonistic action, EDG-5 antagonist is useful for treating and / or preventing for a disease due to vascular constriction, for example, cerebrovascular spasmodic disorder after subarachnoid hemorrhage or stroke, cardiovasucular spasmodic disorder, hypertension, renal disease, cardiac infarction, cardiac angina, arrhythmia, facilitation of the portal blood pressure involved in liver cirrhosis, varicosity involved in liver cirrhosis and the like, or EDG-5 agonist is useful for treating and / or preventing for a disease due to vasodilation of blood vessels, for example, chronic headache (such as migraine, tension-type headache, mixed-type headache thereof, or migrainous neuralgia), haemorrhoid, congestive disorder and the like.

The invention discloses the use of a compound of formula (I), wherein R1, R2, R3, and R4 each independently represents: hydrogen; halo; hydroxy; (C1-C6) alkyl optionally substituted by hydroxy or (C1-C4) alkoxy; (C1-C6) haloalkyl; (C1-C6) alkoxy; and (C1-C6) haloalkoxy; for the preparation of a medicament for the prevention and / or treatment of diseases resulting from opening of the MPTP which are characterized by degenerative tissue damages, in particular, diabetes and diabetic complications, neurological diseases and stroke, heart infarction, inherited dystrophies and hepatitis, more particularly, diabetic vascular diseases, such as diabetic retinopathy, and neurodegenerative disorders, such as multiple sclerosis. Further objects are a group of selected individual compounds of formula (I) for use as medicaments and a further group of selected individual compounds of formula (I) as novel compounds.

The present invention herein discloses potent synergistic compositions of vasoactive mediators enhancers for improving vascular endothelial function. Particularly, the invention relates to synergistic nutritional composition comprising exogenous blend of N1-methyl nicotinamide chloride and standardized red spinach extract enriched with nitrate content along with pharmaceutically acceptable excipients, wherein N1-methyl nicotinamide salt and standardized red spinach extract enriched with nitrate content are present in the ratio of 1:0.5 to 1:8; and N1-methyl nicotinamide chloride and nitrate of standardized red spinach extract, are present in the ratio of 1:0.1 to 1:1. The present synergistic composition is useful for treating endothelial dysfunction such as hypertension, atherosclerosis, thrombosis, myocardial infarction, heart injury.

The invention provides a compound of a formula (I) shown in the specification with selective beta1-adrenergic inhibitory activity, and the chemical name of the compound is clerodane-3,12E-di-double bond-15,16-dioctyl phthalate. The compound of the formula (1) has selective beta1-adrenergic receptor inhibitory activity, the inhibitory activity of the compound upon a beta1 receptor is 6 times or greater of that upon a beta2 receptor, cardiovascular diseases such as hypertension, myocardial ischemia, cardiomegaly, coronary heart diseases, myocardial infarction, stroke, atherosclerosis, cardiac failure and angina pectoris can be effectively treated, and in addition, side effects of a non-selective beta1-adrenergic receptor inhibitor can be avoided. The invention further relates to a pharmaceutically acceptable salt of the compound of the formula (I), a medicine composition and a preparation with the compound of the formula (I) and / or the pharmaceutically acceptable salt thereof, and application of the compounds and compositions in preparing medicines for treating cardiovascular diseases.

The present application discloses a recombinant AAV vector comprising a promoter that targets gene expression to myofibroblast-like lineage of cells in the heart. The present application, also discloses the preparation and use of AAV expression cassettes using a modified periostin promoter that successfully drives gene expression in cardiac myofibroblast-like cells. The present invention encompasses compositions and methods useful for treating myocardial infarction. Further comprising compositions and methods for preparing and using AAV vectors for targeting cells and inducing gene expression. The compositions and methods of the invention are useful for efficiently targeting cardiac myofibroblasts following a cardiac injury, disease, or disorder. Further comprising a kit for effecting alleviation of the various diseases or disorders recited herein.